Silverback Therapeutics【SBTX】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

5.87

買値

2.37

売値

6.15

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

563.502M

前日終値

5.87

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

発行済株式数

95,997,000

配当利回り

PER

-19.21

1 株当たり利益 (EPS)

-0.57

歳入

30k

純利益

-54.37M

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

ars-pharma.com

本社

Wilmington, Delaware, USA

設立

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting Data Support New...

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

SAN DIEGO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering...

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering...

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology...

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in...

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

SBTX - Frequently Asked Questions (FAQ)

What is the current Silverback Therapeutics share price?

The current share price of Silverback Therapeutics is US$ 5.87

How many Silverback Therapeutics shares are in issue?

Silverback Therapeutics has 95,997,000 shares in issue

What is the market cap of Silverback Therapeutics?

The market capitalisation of Silverback Therapeutics is USD 563.5M

What is the 1 year trading range for Silverback Therapeutics share price?

Silverback Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Silverback Therapeutics?

The price to earnings ratio of Silverback Therapeutics is -19.21

What is the cash to sales ratio of Silverback Therapeutics?

The cash to sales ratio of Silverback Therapeutics is 36.27k

What is the reporting currency for Silverback Therapeutics?

Silverback Therapeutics reports financial results in USD

What is the latest annual turnover for Silverback Therapeutics?

The latest annual turnover of Silverback Therapeutics is USD 30k

What is the latest annual profit for Silverback Therapeutics?

The latest annual profit of Silverback Therapeutics is USD -54.37M

What is the registered address of Silverback Therapeutics?

The registered address for Silverback Therapeutics is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801

What is the Silverback Therapeutics website address?

The website address for Silverback Therapeutics is ars-pharma.com

Which industry sector does Silverback Therapeutics operate in?

Silverback Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
ABLVAble View Global Inc	US$ 1.73 (137.18%)	5.14M
SUNESUNation Energy Inc	US$ 0.402999 (127.55%)	482.05M
BTOGBit Origin Ltd	US$ 0.6117 (118.46%)	622.67M
DWTXDogwood Therapeutics Inc	US$ 6.63 (49.66%)	25.92M
KZIAKazia Therapeutics Ltd	US$ 1.1899 (40.80%)	4.5M
ALBTAvalon GloboCare Corporation	US$ 6.96 (-36.15%)	570.43k
SCNXScienture Holdings Inc	US$ 1.55 (-35.68%)	1.54M
ACXPAcurx Pharmaceuticals Inc	US$ 0.4572 (-29.88%)	1.13M
RETOReTo Eco Solutions Inc	US$ 5.42 (-27.73%)	108k
OCTOEightco Holdings Inc	US$ 1.08 (-27.03%)	332.1k
BTOGBit Origin Ltd	US$ 0.6117 (118.46%)	622.67M
SUNESUNation Energy Inc	US$ 0.402999 (127.55%)	482.05M
NVDANVIDIA Corporation	US$ 112.69 (1.92%)	341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10.675 (-0.70%)	143.04M
ICONIcon Energy Corporation	US$ 0.169898 (17.17%)	142.23M

銘柄コード

株価

出来高

BTOGBit Origin Ltd

US$ 0.6117

(118.46%)

622.67M

SUNESUNation Energy Inc

US$ 0.402999

(127.55%)

482.05M

NVDANVIDIA Corporation

US$ 112.69

(1.92%)

341.94M

TSLLDirexion Daily TSLA Bull 2X Trust ETF

US$ 10.675

(-0.70%)

143.04M

ICONIcon Energy Corporation

US$ 0.169898

(17.17%)

142.23M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Silverback Therapeutics Inc (SBTX)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Silverback Therapeutics Inc について

SBTX 最新ニュース

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

SBTX - Frequently Asked Questions (FAQ)

ムーバー

SBTX 財務

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Silverback Therapeutics Inc (SBTX) 銘柄情報

Silverback Therapeutics Inc (SBTX)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Silverback Therapeutics Inc について

SBTX 最新ニュース

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

Silverback Therapeutics and ARS Pharmaceuticals Announce Merger

Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results

SBTX - Frequently Asked Questions (FAQ)

ムーバー

SBTX 財務

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS